Geron Corporation (GERN)
NASDAQ:GERN
Want to see GERN full AI Analyst Report?
GERN Stock Chart & Stats
$1.69
<$0.01(0.15%)
At close: 4:00 PM EST
$1.69
<$0.01(0.15%)
Day’s Range― - ―
52-Week Range$1.04 - $2.01
Previous CloseN/A
Volume1.63M
Average Volume (3M)19.39M
Market Cap
$1.08B
Enterprise Value$1.25B
Total Cash (Recent Filing)$359.80M
Total Debt (Recent Filing)$251.57M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
May 11, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding640,544,700
10 Day Avg. Volume21,231,027
30 Day Avg. Volume19,393,853
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)3.90
Price to Sales (P/S)4.79
P/FCF Ratio-7.92
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue6.82
Enterprise Value/Gross Profit7.94
Enterprise Value/Ebitda-24.08
Forecast
1Y Price Target
$3.25Price Target Upside92.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$229.32M
Bulls Say, Bears Say
Bulls Say
Commercial Rollout And AdoptionThe commercial launch of Rytelo is showing increasing demand with a growing base of ordering accounts and rising use in earlier lines of therapy, indicating expanding market acceptance beyond initial patient groups.
Financial FlexibilitySubstantial cash reserves, access to additional debt financing, and disciplined spending provide financial flexibility to support the Rytelo launch and a path toward breakeven.
Revenue Guidance And Growth OutlookManagement reiterated revenue guidance and signaled that new marketing and commercial initiatives are expected to accelerate sales, supporting analyst confidence in the company's growth trajectory.
Bears Say
Commercial Penetration RiskCommercial strategy relies on expanding use in second-line patients but current patient penetration remains low and early provider interest has not consistently translated into revenue.
Net Revenue PressureRising gross-to-net adjustments, partly driven by contracts with group purchasing organizations in community settings, are reducing net revenue per unit and could constrain overall revenue growth.
Weak Near-term Sales PerformanceReported revenue fell short of analyst expectations and Rytelo sales were flat, undermining near-term revenue momentum and investor confidence.
Geron News
GERN FAQ
What was Geron Corporation’s price range in the past 12 months?
Geron Corporation lowest stock price was $1.04 and its highest was $2.01 in the past 12 months.
What is Geron Corporation’s market cap?
Geron Corporation’s market cap is $1.08B.
When is Geron Corporation’s upcoming earnings report date?
Geron Corporation’s upcoming earnings report date is May 11, 2026 which is in 25 days.
How were Geron Corporation’s earnings last quarter?
Geron Corporation released its earnings results on Nov 01, 2018. The company reported -$0.03 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.03.
Is Geron Corporation overvalued?
According to Wall Street analysts Geron Corporation’s price is currently Undervalued.
Does Geron Corporation pay dividends?
Geron Corporation does not currently pay dividends.
What is Geron Corporation’s EPS estimate?
Geron Corporation’s EPS estimate is -0.02.
How many shares outstanding does Geron Corporation have?
Geron Corporation has 640,544,700 shares outstanding.
What happened to Geron Corporation’s price movement after its last earnings report?
Geron Corporation reported an EPS of -$0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -11.795%.
Which hedge fund is a major shareholder of Geron Corporation?
Currently, no hedge funds are holding shares in GERN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Geron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.25 (92.31% Upside)
$3.25 (92.31% Upside)
Blogger Sentiment
Bullish
GERN Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 5.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.20%
12-Months-Change
Fundamentals
Return on Equity
-34.23%
Trailing 12-Months
Asset Growth
-3.93%
Trailing 12-Months
Company Description
Geron Corporation
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
GERN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive commercial and clinical story: substantial year-over-year revenue growth as Rytelo completed its first full commercial year, meaningful Q4 demand and prescriber gains, clear 2026 revenue guidance and a focused second-line strategy targeting ~8,000 U.S. patients. Clinical progress (fully enrolled IMPACT MF trial, multiple ISTs and upcoming real-world data) and a streamlined cost structure that targets lower operating expenses in 2026 are further positives. Offsetting risks include an operating loss in 2025 (expenses exceed revenue), a ~20% decline in cash year-over-year and higher gross-to-net deductions (expected to remain in the high teens to low 20s), plus European reimbursement and pricing uncertainty. On balance, the company appears positioned for growth with manageable near-term financial and access risks.View all GERN earnings summariesGERN Stock 12 Month Forecast
Average Price Target
$3.25
▲(92.31% Upside)
Technical Analysis
Ownership Overview
0.06% Insiders
11.09% Mutual Funds
37.85% Other Institutional Investors
36.10% Public Companies and
Individual Investors